Vor Biopharma Inc.
VOR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001817229
In the last 90 days, Vor Biopharma Inc. insiders filed 0 open-market purchases and 1 sale; 102 institutions reported holding it in 13F filings for Q2 2026, worth $893.0M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Vor Biopharma Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 71 | 1 | 54 | −16 |
| Shares | 54.5M | 497.7K | 47.8M | −6.20M (−11.5%) |
| Value | $54.5M | $497.7K | $33.5M | −$20.6M (−38.0%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (10)
Institutions that held Vor Biopharma Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Hudson Bay Capital Management LP | 2,466,236 | $1.73M | 0.01% |
| Cowen and Company, LLC | 1,220,590 | $854.4K | 0.03% |
| BlackRock, Inc. | 487,654 | $341.4K | 0.00% |
| Two Sigma Investments, LP | 137,134 | $96.0K | 0.00% |
| Rosalind Advisors, Inc. | 76,685 | $53.7K | 0.04% |
| Two Sigma Advisers, LP | 50,300 | $35.2K | 0.00% |
| Nomura Holdings Inc | 41,495 | $29.0K | 0.00% |
| Chiron Capital Management, LLC | 11,000 | $7.70K | 0.01% |
| Simplex Trading, LLC | 5,053 | $3.00K | 0.00% |
| Royal Bank of Canada | 55 | $0 | 0.00% |
Sold out (26)
Institutions that held Vor Biopharma Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Paradigm Biocapital Advisors LP | 6,457,293 | $6.46M |
| Susquehanna International Group, LLP | 247,167 | $247.2K |
| Y-Intercept (Hong Kong) Ltd | 132,298 | $132.3K |
| Centiva Capital, LP | 77,800 | $77.8K |
| Cubist Systematic Strategies, LLC | 52,914 | $52.9K |
| Squarepoint Ops LLC | 52,287 | $52.3K |
| Paloma Partners Management Co | 35,100 | $35.1K |
| HRT Financial LP | 31,855 | $31.0K |
| Bank of Montreal | 22,488 | $27.9K |
| Mirae Asset Global ETFs Holdings Ltd. | 19,524 | $19.5K |
| SEI Investments Co | 17,596 | $17.6K |
| Virtu Financial LLC | 12,370 | $12.0K |
| Jump Financial, LLC | 11,328 | $11.3K |
| AQR Capital Management LLC | 11,204 | $11.2K |
| UBS Group AG | 11,201 | $11.2K |
| Citigroup Inc | 6,456 | $6.46K |
| Rhumbline Advisers | 5,505 | $5.50K |
| ProShare Advisors LLC | 5,111 | $5.11K |
| Macquarie Group Ltd | 1,945 | $1.95K |
| Russell Investments Group, Ltd. | 1,231 | $1.23K |
| NBC Securities, Inc. | 1,000 | $1.00K |
| New York State Common Retirement Fund | 322 | $322 |
| Group One Trading, L.P. | 229 | $229 |
| Smartleaf Asset Management LLC | 102 | $116 |
| Lazard Asset Management LLC | 65 | $0 |
| CWM, LLC | 34 | $0 |
Not filed for Q3 2024 yet (1)
Institutions that held Vor Biopharma Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 497,696 | $497.7K |